Pharmanovia Enters Into an Exclusive Licensing Agreement With Aeterna Zentaris for the First and Only Orally Administered Approved Medicine for the Diagnosis of Growth Hormone Deficiency in Adults
16.3.2023 15:50:00 EET | Business Wire | Press release
Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the expansion of its endocrinology portfolio with a new licensing agreement for GHRYVELIN™ (macimorelin), a novel medicine used for diagnosing Adult Growth Hormone Deficiency (AGHD) from Aeterna Zentaris.
The agreement gives Pharmanovia the exclusive commercial rights in the UK and EEA.
AGHD is a rare and serious condition that affects 2 to 3 people in 10,000 with significant risk of morbidity and reduced quality of life. It is underdiagnosed and often missed in patients.1
It is characterised by a number of variable and common symptoms including reduced energy levels, altered body composition, osteoporosis (reduced bone mineral density), reduced muscle strength, lipid abnormalities such as increased LDL cholesterol, insulin resistance, and impaired cardiac function.2
Pharmanovia CEO, Dr James Burt commented; ‘’Endocrinology is the largest of our four core therapy areas and the in-licensing of this important novel medicine, the second in-licensing deal of a novel medicine in almost as many weeks, speaks to our ability to in-licence novel, complementary products in the therapeutic settings we support.”
“We are well placed to use the knowledge and the platform we’ve built through our current endocrinology work to ensure that more patients get the diagnosis they need for this rare and serious condition. Furthermore today’s announcement presents a rare opportunity to license in a medicine that naturally synergises with one of the core growth products in our current portfolio.”
Dr Klaus Paulini, CEO of Aeterna Zentaris, added: “Pharmanovia has expertise marketing diagnostic testing solutions combined with an established footprint in endocrinology across Europe, so this partnership was a natural choice. We’re excited to leverage their knowledge to ensure that more patients benefit from an improved testing experience and reduction in unnecessary treatment for patients.”
About Pharmanovia
Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.
We do this by enhancing established medicines either by rediscovering, repurposing or re-engineering iconic brands to improve patient outcomes and experiences both through in-house development and through strategic partnerships.
Our diverse and growing team operate in over 160 countries across the globe, delivering high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology.
About Aeterna Zentaris
Aeterna Zentaris is a specialty biopharmaceutical company developing and commercialising a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen™; Ghryvelin®), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need, in collaboration with Novo Nordisk.
About Macimorelin
Macimorelin is marketed under the brand name GHRYVELIN™ (macimorelin) in the UK and European Economic Area.
GHRYVELIN™ a ghrelin agonist, is an orally active small molecule that stimulates the secretion of growth hormone from the pituitary gland. Stimulated growth hormone levels are measured in blood samples after oral administration of GHRYVELIN™ for the assessment of AGHD. of GHRYVELIN™ was granted in 2019, based on Phase III data showing that oral macimorelin provides accuracy comparable to that of standard insulin tolerance testing (ITT)4, but has a more favourable safety profile compared to ITT. Oral GHRYVELIN™ also reduces false positive test results, helping to avoid unnecessary treatment of patients.3
References
1 J Endocr Soc. 2022 Jul 1; 6(7): bvac077. Andrew R Hoffman, Tracy Mathison, Deno Andrews, Kristine Murray, Nicky Kelepouris, and Maria Fleseriu - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165431/ -last accessed 1.3.2023
2 Yuen KCJ, Biller BMK, Radovick S, et al -. Endocr Pract. 2019;25(11):1191-1232. https://pubmed.ncbi.nlm.nih.gov/31760824/ - last accessed 1.3.2023
3 Garcia JM et al. Macimorelin as a Diagnostic Test for Adult GH Deficiency. J Clin Endocrinol Metab, 2018, 103(8): 3083-3093 - https://pubmed.ncbi.nlm.nih.gov/29860473/ - last accessed 1.3.2023
4 https://www.ema.europa.eu/en/documents/assessment-report/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-public-assessment-report_en.pdf – last accessed 1.3.2023
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005846/en/
Contact information
For further information:
Alison Dyson, Director of Communications, Pharmanovia
07442 256310/ alison.dyson@pharmanovia.com
Or pharmanovia@67health.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KAYTUS Enhances KSManage with Full-Stack O&M Visibility for AI Data Centers26.2.2026 10:02:00 EET | Press release
As AI data centers scale to support increasingly complex AI workloads, traditional IT monitoring can no longer provide the visibility required for reliable operations. KAYTUS, a leading provider of end-to-end AI and liquid cooling solutions, has significantly upgraded KSManage, introducing full-stack, four-level visibility across components, servers and cabinets, clusters, and AI jobs, to address the challenges of complex troubleshooting, higher component failure rates, intricate application dependencies and delayed responses to operations and maintenance (O&M) incidents generated by demanding AI data center operations. The enhanced platform enables precise fault localization, faster incident response, and proactive operations. With KSManage, KAYTUS helps customers maximize availability, improve operational efficiency, and ensure the stability of mission-critical AI data centers powering next-generation computing. Four Key Challenges Constrain the Operational Efficiency of AI Data Cent
NIPPON KINZOKU to Expand Sales of Ultra-Light Magnesium Alloy Foil: Empowering the Future with Eco-Product26.2.2026 10:01:00 EET | Press release
NIPPON KINZOKU CO., LTD. (TOKYO: 5491) (Headquarters: Minato-ku, Tokyo) is proud to announce a strategic expansion in the sales of its Magnesium Alloy Foil. Positioned as a core "Eco-Product" that contributes to reducing environmental impact, this high-performance material addresses diverse industrial needs by offering the lightest weight among practical metals combined with exceptional vibration-damping properties. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226621455/en/ Magnesium Alloy Foil (Alloy: AZ31B, Thickness: 0.05 mm, Width: 100 mm) Magnesium alloy is gaining global attention for its incredibly low specific gravity approximately 1/4.5 that of steel and 1/2.5 that of titanium—while maintaining excellent specific strength, stiffness, and damping performance. Target Markets: Beyond mobile PCs and high-end smartphones, we expect significant growth in the expanding XR device market. XR (Extended Reality): A collec
Mobileum Enables GSMA Industry Services’ Launch of VOLTIS 5G Extension, Streamlining Global 5G Roaming Verification26.2.2026 10:00:00 EET | Press release
Mobileum Inc. (“Mobileum”), a leading global provider of analytics and network solutions, today announced its expanded role in enabling GSMA Industry Services’ launch of the VOLTIS (Voice over LTE Interoperability & Testing Service) 5G Extension Verification Program. The new extended program goes beyond the existing VoLTE/IMS verification framework to include 5G readiness verification, providing operators with a standardized path to validate next-generation roaming and interoperability. As an appointed verification partner, Mobileum manages the end-to-end validation process, from test planning and resource validation through test execution, troubleshooting, and final reporting, delivering a streamlined, globally recognized verification experience for operators worldwide. As 5G roaming scales globally, operators face increased complexity in validating VoLTE and 5G interoperability across international partners. The VOLTIS 5G Extension offers a standardized verification path that helps o
Lone Star Agrees to Acquire Central London Office Building26.2.2026 09:51:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Real Estate Fund VII, L.P. has reached an agreement to acquire 90 Whitfield Street in London, UK from Derwent London. The property, located in central London’s West End sub-market of Fitzrovia, is comprised of 107,000 total square-feet with 99,000 square-feet dedicated to fully developed office space and a retail space on the ground floor of 8,000 square-feet. The building offers highly desirable styling including floor-to-ceiling glazing and generous heights, flexible floor plates, a recently refurbished reception space and large central atrium, and the property’s top floor includes its own privately accessed 900 square-foot rooftop terrace. The asset is also located on an attractive corner position that affronts Tottenham Court Road, one of London’s principal thoroughfares, and is within walking distance of six separate tube stations providing access from across the greater metropolitan area. “We have strong
INNIO signs Definitive Agreement to Acquire Enerflex APAC Operations, Expanding Service Capabilities in the Asia-Pacific Region26.2.2026 08:34:00 EET | Press release
INNIO Group, a leading energy solution and service provider, today announced it has signed a definitive agreement with Enerflex Ltd. (TSX: EFX) (NYSE: EFXT) to acquire their aftermarket business operations in Australia, Thailand and Indonesia. The transaction advances INNIO’s strategy to strengthen its presence in the Asia-Pacific (APAC) region and enhance customer proximity. The transaction is subject to customary closing conditions and regulatory approvals. Closing is expected during the second half of 2026. The Enerflex APAC aftermarket business operates principally in three countries and eight locations. The company offers extensive workshop and office space, as well as a strong installed base. This base is supported by long-term service agreements with major oil and gas companies. Dr. Dennis Schulze, CFO of INNIO Group, commented: “By integrating Enerflex’s expertise in the APAC region, we strengthen our service portfolio, deliver greater customer value, and accelerate growth in A
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom